Haq K, Lin S, Dasgupta A, Obaidi Z, Bagnasco S, Maggiore U
BMC Nephrol. 2024; 25(1):433.
PMID: 39609684
PMC: 11606107.
DOI: 10.1186/s12882-024-03846-x.
Muff-Luett M, Sanderson K, Engen R, Zahr R, Wenderfer S, Tran C
Pediatr Nephrol. 2021; 36(8):2349-2360.
PMID: 33693990
PMC: 8263513.
DOI: 10.1007/s00467-021-04965-5.
Anliker-Ort M, Dingemanse J, van den Anker J, Kaufmann P
Front Immunol. 2020; 11:599417.
PMID: 33362783
PMC: 7758461.
DOI: 10.3389/fimmu.2020.599417.
Kant S, Bhalla A, Alasfar S, Alachkar N
BMC Nephrol. 2020; 21(1):189.
PMID: 32434487
PMC: 7238522.
DOI: 10.1186/s12882-020-01847-0.
Andrighetto S, Leventhal J, Zaza G, Cravedi P
Int J Mol Sci. 2020; 20(24).
PMID: 31888179
PMC: 6940904.
DOI: 10.3390/ijms20246336.
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.
Menne J, Delmas Y, Fakhouri F, Kincaid J, Licht C, Minetti E
Clin Kidney J. 2019; 12(2):196-205.
PMID: 30976396
PMC: 6452204.
DOI: 10.1093/ckj/sfy035.
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome.
Siedlecki A, Isbel N, Walle J, James Eggleston J, Cohen D
Kidney Int Rep. 2019; 4(3):434-446.
PMID: 30899871
PMC: 6409407.
DOI: 10.1016/j.ekir.2018.11.010.
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Wijnsma K, Duineveld C, Wetzels J, van de Kar N
Pediatr Nephrol. 2018; 34(11):2261-2277.
PMID: 30402748
PMC: 6794245.
DOI: 10.1007/s00467-018-4091-3.
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
Brocklebank V, Kavanagh D
Clin Kidney J. 2017; 10(5):600-624.
PMID: 28980670
PMC: 5622895.
DOI: 10.1093/ckj/sfx081.
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C
Clin Kidney J. 2017; 10(3):310-319.
PMID: 28621343
PMC: 5466111.
DOI: 10.1093/ckj/sfw115.
A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.
Quiroga B, de Lorenzo A, Vega C, de Alvaro F
Am J Case Rep. 2016; 17:950-956.
PMID: 27974740
PMC: 5179232.
DOI: 10.12659/ajcr.899764.
Advances and challenges in the management of complement-mediated thrombotic microangiopathies.
Davin J, van de Kar N
Ther Adv Hematol. 2015; 6(4):171-85.
PMID: 26288712
PMC: 4530367.
DOI: 10.1177/2040620715577613.
Treatment of atypical uraemic syndrome in the era of eculizumab.
Fremeaux-Bacchi V
Clin Kidney J. 2015; 5(1):4-6.
PMID: 26069738
PMC: 4400466.
DOI: 10.1093/ckj/sfr177.
Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.
Magro C, Momtahen S, Mulvey J, Yassin A, Kaplan R, Laurence J
Am J Dermatopathol. 2015; 37(5):349-56.
PMID: 25893747
PMC: 4405909.
DOI: 10.1097/DAD.0000000000000234.
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle A, Ogawa M
Blood. 2015; 125(21):3253-62.
PMID: 25833956
PMC: 4449039.
DOI: 10.1182/blood-2014-09-600411.
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Licht C, Greenbaum L, Muus P, Babu S, Bedrosian C, Cohen D
Kidney Int. 2015; 87(5):1061-73.
PMID: 25651368
PMC: 4424817.
DOI: 10.1038/ki.2014.423.
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.
Schramm E, Roumenina L, Rybkine T, Chauvet S, Vieira-Martins P, Hue C
Blood. 2015; 125(15):2359-69.
PMID: 25608561
PMC: 4392009.
DOI: 10.1182/blood-2014-10-609073.
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.
Alasfar S, Alachkar N
Front Med (Lausanne). 2015; 1:52.
PMID: 25593925
PMC: 4292050.
DOI: 10.3389/fmed.2014.00052.
A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation.
Broeders E, Stordeur P, Rorive S, Dahan K
BMJ Case Rep. 2014; 2014.
PMID: 25538218
PMC: 4275717.
DOI: 10.1136/bcr-2014-207630.
Current treatment of atypical hemolytic uremic syndrome.
Kaplan B, Ruebner R, Spinale J, Copelovitch L
Intractable Rare Dis Res. 2014; 3(2):34-45.
PMID: 25343125
PMC: 4204535.
DOI: 10.5582/irdr.2014.01001.
